211.95BMarket Cap35.88P/E (TTM)
68.785High68.160Low4.01MVolume68.250Open68.530Pre Close274.15MTurnover0.13%Turnover Ratio35.88P/E (Static)3.10BShares74.90852wk High5.41P/B211.15BFloat Cap59.55452wk Low1.45Dividend TTM3.09BShs Float74.908Historical High2.12%Div YieldTTM0.91%Amplitude5.406Historical Low68.437Avg Price1Lot Size
AstraZeneca Stock Forum
🎯 Ph 3 readouts in Q2 2024...
$CG Oncology(CGON.US)$ Phase 3
$United Therapeutics(UTHR.US)$ Phase 3
$United Therapeutics(UTHR.US)$ Phase 3
$BioCardia(BCDA.US)$ Phase 3
$Insmed(INSM.US)$ Phase 3
$GlycoMimetics(GLYC.US)$ Phase 3
$Annexon(ANNX.US)$ Phase 3
$Lipocine(LPCN.US)$ Phase 3
$FibroGen(FGEN.US)$ Phase 3
$UroGen Pharma Ltd(URGN.US)$ Phase 3
$Lyra Therapeutics(LYRA.US)$ Phase 3
$Citius Pharmaceuticals(CTXR.US)$ Phase 3
$Jaguar Health(JAGX.US)$ Phas...
FDA PDUFA Update…
$Supernus Pharmaceuticals(SUPN.US)$ : CRL 4/8/24 🙁
⇒ SPN-830
⇒ OFF episodes in PD
⇒ NDA
⇒ PDUFA: 4/5/24
$Legend Biotech(LEGN.US)$ & $Johnson & Johnson(JNJ.US)$ : Approved 🎉
⇒ CARVYKTI (cilta-cel)
⇒ Multiple myeloma
⇒ sBLA
⇒ PDUFA: 4/5/24
$AstraZeneca(AZN.US)$ : Approved 🎉
⇒ Enhertu
⇒ HER2+ solid tumors
⇒ sBLA
⇒ PDUFA: Q2 2024
$2seventy bio(TSVT.US)$ & $Bristol-Myers Squibb(BMY.US)$ : Approved 🎉
⇒ Abecma
⇒ Multiple myeloma
⇒ sBLA
⇒ Delayed PDUFA
$Vanda Pharmaceuticals(VNDA.US)$...
FDA PDUFA Update…
$Akebia Therapeutics(AKBA.US)$ : Approved 🎉
⇒ Vafseo (Vadadustat)
⇒ Anemia due to CKD
⇒ NDA
⇒ PDUFA: 3/27/24
$Merck & Co(MRK.US)$ : Approved 🎉
⇒ WINREVAIR (sotatercept)
⇒ Pulmonary arterial hypertension
⇒ BLA
⇒ PDUFA: 3/26/24
$AstraZeneca(AZN.US)$ : Approved 🎉
⇒ Ultomiris (ravulizumab)
⇒ NMOSD
⇒ sBLA
$Regeneron Pharmaceuticals(REGN.US)$ : CRL 🙁
⇒ Odronextamab
⇒ r/r FL and r/r DLBCL
⇒ BLA
⇒ PDUFA: 3/31/24
📌 This week’s PDUFAs: 🚨
$AstraZeneca(AZN.US)$ : 🤔
⇒...
Updated Complete & Utter M&A Guesses Purely for Entertainment Purposes:
$Merck & Co(MRK.US)$ x $Immunovant(IMVT.US)$
$Eli Lilly and Co(LLY.US)$ x $Cytokinetics(CYTK.US)$ (and soon)
$Regeneron Pharmaceuticals(REGN.US)$ x $Apellis Pharmaceuticals(APLS.US)$ (panache & brash)
$Gilead Sciences(GILD.US)$ x %$Madrigal Pharmaceuticals(MDGL.US)$ (liver king)
$Bristol-Myers Squibb(BMY.US)$ x $Iovance Biotherapeutics(IOVA.US)$ (cell Tx boost needed)
$Eli Lilly and Co(LLY.US)$ x $Merus(MRUS.US)$ (partner n...
Biotech Stock Catalyst Watchlist
$Intra-Cellular Therapies(ITCI.US)$ Phase 3
$CG Oncology(CGON.US)$ Phase 3
$Hutchmed (China)(HCM.US)$ Phase 3
$Viracta Therapeutics(VIRX.US)$ Phase 3
$GlycoMimetics(GLYC.US)$ Phase 3
$Annexon(ANNX.US)$ Phase 3
$Lipocine(LPCN.US)$ Phase 3
$FibroGen(FGEN.US)$ Phase 3
$UroGen Pharma Ltd(URGN.US)$ Phase 3
$Lyra Therapeutics(LYRA.US)$ Phase 3
$Citius Pharmaceuticals(CTXR.US)$ Phase 3
$Marinus Pharmaceuticals(MRNS.US)$ Phase 3
$BioCardia(BCDA.US)$ Phase 3...
neuromyelitis optica spectrum disorder (NMOSD)
⇒ sBLA approved as 4th indication 👏
⇒ 1st and only long-acting C5 complement inhibitor,
offers Px with AQP4 Ab+
⇒ CHAMPION-NMOSD trial - met primary endpoint 🔬
⇒ Ultomiris (ravulizumab-cwvz) inj., for IV use 💉
ColumnsWall Street Today | Market Reverses, Decides Big Chips Are Good
Stocks closed higher Tuesday, ramping up from a morning pullback as the market reacted to the news that $NVIDIA(NVDA.US)$ announced a large computer chip for AI processing at its GTC event Monday night. Investors await the FOMC policy statement on Wednesday, where the market has priced in a 99% chance of no rate change.
With preliminary numbers, the $S&P 500 Index(.SPX.US)$ climbed 0.56% to its 18th record close of the year at ...
It is starting to look like a double bottom on the weekly candles.
The price action of BMY is finding support near the 47.50 price point. It appears to be forming a double bottom on the charts so far.
There is a bullish divergence on several of the popular oscillating indicators for the weekly candles. The major indicators for the daily candles, like RSI and MACD, are all officially in bullish territory.
Ultimately, the price would need to climb out of the trading ...
No comment yet